Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial

BACKGROUND: Molecular studies suggest inhibition of colorectal mucosal polyamines (PAs) may be a promising approach to prevent colorectal cancer (CRC). Inhibition of ornithine decarboxylase (ODC) using low-dose eflornithine (DFMO, CPP-1X), combined with maximal PA export using low-dose sulindac, res...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Carol A., Dekker, Evelien, Samadder, N. Jewel, Stoffel, Elena, Cohen, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969736/
https://www.ncbi.nlm.nih.gov/pubmed/27480131
http://dx.doi.org/10.1186/s12876-016-0494-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969736/
https://www.ncbi.nlm.nih.gov/pubmed/27480131
http://dx.doi.org/10.1186/s12876-016-0494-4

Ejemplares similares